UNSPSC 51152064: Orphenadrine citrate

This classification denotes a muscle relaxant with the molecular formula C18H23NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0A40N8I4S, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but more generally known as orphenadrine citrate, which bears US NIH Compound Identifier 4601. European Medicines Agency schedules Orphenadrine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03546MIG.

UNSPSC 51152064 Orphenadrine citrate is a Commodity code for a specific muscle-relaxant pharmaceutical product, yet the recent state and local opportunities tagged under it do not reflect procurement of orphenadrine citrate itself. Instead, the code shows activity in naloxone (opioid antagonist) procurement and exploratory pharmacy benefit program restructuring, indicating a significant mismatch between the code's nominal scope and what jurisdictions are actually buying under this tag. The few recent opportunities on record suggest that state and local governments are using this code — or related codes in the pharmaceutical family — to solicit emergency response medications and pharmacy services, but the actual products and services do not align with the orphenadrine citrate chemical identity. Issuing bodies in the recent record include a county government (Seminole County, Florida) procuring naloxone and drug deactivation systems for community health, and a state health and human services commission (Texas HHS) conducting market research on direct-to-manufacturer prescription programs. The scope of work being solicited spans product procurement (naloxone units for emergency response) and preliminary vendor qualification for pharmacy program innovation, neither of which involves orphenadrine citrate specifically.

Activity is sparse and geographically scattered. Seminole County, Florida released an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2026, with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI on April 3, 2026, to explore vendor capabilities for direct-to-manufacturer prescription programs as a preliminary market intelligence phase before formal solicitation. No other recent state or local opportunities appear under this code. The mismatch between the code's pharmaceutical identity and the actual procurements suggests either a tagging error in the underlying data or a broader family-code application that overshadows the specific commodity. Given the sparse and unaligned activity, orphenadrine citrate as a discrete procurement line does not show meaningful current momentum in state and local markets.